We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

156 hedge funds and large institutions have $429M invested in Keros Therapeutics in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

23% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 40

0.13% less ownership

Funds ownership: 90.72% → 90.59% (-0.13%)

4% less first-time investments, than exits

New positions opened: 48 | Existing positions closed: 50

3% less funds holding

Funds holding: 161 → 156 (-5)

26% less capital invested

Capital invested by funds: $582M → $429M (-$153M)

27% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $17M

Holders
156
Holders Change
-5
Holders Change %
-3.11%
% of All Funds
2.09%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
48
Increased
49
Reduced
40
Closed
50
Calls
$12.5M
Puts
$17M
Net Calls
-$4.54M
Net Calls Change
-$4.16M

Top Buyers

1
N
Nuveen
North Carolina
+$44.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$27.7M
3
LGM
Logos Global Management
California
+$23.2M
4
ACM
ADAR1 Capital Management
Texas
+$17M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$14.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$59.2M
2
B
Braidwell
Connecticut
-$30M
3
DGM
Darwin Global Management
Jersey
-$26.7M
4
Holocene Advisors
Holocene Advisors
New York
-$19M
5
JFG
Jefferies Financial Group
New York
-$13.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
1
Nuveen
North Carolina
$94.5M +$44.9M +3,867,970 +4,866%
BlackRock
2
BlackRock
New York
$28.4M +$650K +55,959 +2%
JP Morgan Chase
3
JP Morgan Chase
New York
$26.5M +$27.7M +2,387,026 +1,118%
Vanguard Group
4
Vanguard Group
Pennsylvania
$26.2M +$7.07M +609,212 +31%
LGM
5
Logos Global Management
California
$20.4M +$23.2M +2,000,000 New
Morgan Stanley
6
Morgan Stanley
New York
$17.3M +$12.1M +1,040,756 +158%
NCM
7
Nantahala Capital Management
Connecticut
$15.4M +$6.87M +591,742 +65%
ACM
8
ADAR1 Capital Management
Texas
$15.1M +$17M +1,463,215 +6,294%
State Street
9
State Street
Massachusetts
$13.3M +$1.15M +99,156 +8%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$12.9M +$14.5M +1,251,031 +10,340%
Federated Hermes
11
Federated Hermes
Pennsylvania
$12.5M +$12.8M +1,099,519 +882%
TCM
12
Tang Capital Management
California
$11.2M +$12.8M +1,100,000 New
O
13
OrbiMed
New York
$10.4M – – –
Alkeon Capital Management
14
Alkeon Capital Management
New York
$8.67M -$2.91M -250,489 -23%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$8.22M +$473K +40,749 +5%
Goldman Sachs
16
Goldman Sachs
New York
$7.55M +$2.38M +205,022 +38%
RG
17
Redmile Group
California
$5.63M – – –
DS
18
DRW Securities
Illinois
$4.74M +$5.4M +464,895 New
Fidelity Investments
19
Fidelity Investments
Massachusetts
$4.5M -$59.2M -5,101,768 -92%
RC
20
Rangeley Capital
Connecticut
$4.16M +$4.74M +408,234 New
CCM
21
Catalio Capital Management
New York
$3.97M -$208K -17,908 -4%
Northern Trust
22
Northern Trust
Illinois
$2.96M -$75K -6,456 -2%
PP
23
PDT Partners
New York
$2.81M +$3.21M +276,060 New
IC
24
Ikarian Capital
Texas
$2.79M +$3.18M +274,009 New
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
$2.79M +$3.17M +273,342 New
1
2 3 4 5

KROS Hedge Fund Activity: Q1 2025 in Review

156 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2025, worth a combined $429M — down 26% from $582M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of KROS and 48 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 49 added.

The largest buyer was Nuveen, adding an estimated $44.9M. The largest seller was Fidelity Investments, cutting an estimated $59.2M.

  • 156 institutional investors held Keros Therapeutics (KROS) as of Q1 2025, down from 161 in Q4 2024.
  • Funds reported $429M of Keros Therapeutics stock for Q1 2025, down 26% quarter-over-quarter.
  • 48 funds opened new Keros Therapeutics positions in Q1 2025 and 50 closed out, a net change of -2 holders.
  • The largest Keros Therapeutics buyer in Q1 2025 was Nuveen, an estimated $44.9M added.
  • The largest Keros Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $59.2M sold.

Based on aggregated 13F filings for Q1 2025.